These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21166517)

  • 21. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
    Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy for locally recurrent prostate cancer.
    Kirkpatrick JP; Anscher MS
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):933-42. PubMed ID: 16555435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen.
    Swanson GP; Du F; Michalek JE; Hermans M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):62-8. PubMed ID: 20646861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic options for a rising PSA after radical prostatectomy.
    Carthon BC; Marcus DM; Herrel LA; Jani AB; Rossi PJ; Canter DJ
    Can J Urol; 2013 Jun; 20(3):6748-55. PubMed ID: 23783041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].
    Quero L; Mongiat-Artus P; Ravery V; Hennequin V; Maylin C; Desgrandchamps F; Hennequin C
    Cancer Radiother; 2009 Jul; 13(4):267-75. PubMed ID: 19446487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
    Sandler HM; Eisenberger MA
    J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
    Rogers E; Ohori M; Kassabian VS; Wheeler TM; Scardino PT
    J Urol; 1995 Jan; 153(1):104-10. PubMed ID: 7526002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA relapse prostate cancer: the importance of tailored therapy.
    Aranha O; Vaishampayan U
    Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
    Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rising prostate-specific antigen after primary prostate cancer therapy.
    Ward JF; Moul JW
    Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.
    Bernard JR; Buskirk SJ; Heckman MG; Diehl NN; Ko SJ; Macdonald OK; Schild SE; Pisansky TM
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):735-40. PubMed ID: 19464818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.